FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:958-961 March 27, 1997 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Corey, L. Related Article by Horsburgh, C. R. Related Article by Hammer, S. M. Related Article by Katzenstein, D. A. PubMed Citation

To the Editor: In their editorial, Corey and Holmes (Oct. 10 issue)¹ state, "All persons with HIV [human immunodeficiency virus] infection who have CD4 cell counts below 500 cells per cubic millimeter should be encouraged to begin antiretroviral therapy." Such an early instigation of therapy is in line with the current understanding of HIV infection and experience with other infectious diseases, but we do not yet know whether we have good enough therapies — those that have negligible long-term risks and do not jeopardize the efficacy of future therapies the patient may be given — to say that this statement . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.